American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jul 2015
Determining the Ideal Strategy for Ventilator-Associated Pneumonia Prevention: Cost-Benefit Analysis.
Ventilator-associated pneumonia (VAP) is a common healthcare-associated infection with high associated cost and poor patient outcomes. Many strategies for VAP reduction have been evaluated. However, the combination of strategies with the optimal cost-benefit ratio remains unknown. ⋯ Despite their infrequent use, current data suggest that the use of prophylactic probiotics and subglottic endotracheal tubes are cost-effective for preventing VAP from the societal and hospital perspectives.